Nano Dimension Ltd - ADR vs 10X Genomics Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.56 (market cap $328.52M), while 10X Genomics Inc trades at $81.19 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 30.7× Nano Dimension Ltd - ADR's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nano Dimension Ltd - ADR for 43 Days and 10X Genomics Inc for 91 Days on average.
| NNDM | TXG | |
|---|---|---|
Market Cap | $328.52M | $10.07B |
Volume | 1,160,945 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $2.14 | $97.74 |
52-Week Low | $1.21 | $11.48 |
Typical Hold Time | 43 Days | 91 Days |
Enterprise Value | -$76.33M | $9.59B |
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.555, showing modest daily gains of 0.32%. The technical picture remains bearish with negative moving average signals, while fundamentals reveal significant challenges including a -135.18% net income margin and persistent cash burn. Recent developments include leadership changes and strategic divestitures aimed at reducing annual cash burn by $25 million, with the MarkForged sale expected to close in late 2026.
Despite trading below book value (P/B 0.68), NNDM faces substantial execution risks amid ongoing losses and negative cash flow. The company's restructuring efforts and asset sales provide potential catalysts, but investors should weigh the high-risk profile against the discounted valuation. Near-term performance hinges on successful cost reduction and revenue stabilization.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →